PPIDT00493

Drug Information
NameBebtelovimab
SequenceQITLKESGPTLVKPTQTLTLTCTFSGFSLSISGVGVGWLRQPPGKALEWLALIYWDDDKRYSPSLKSRLTISKDTSKNQVVLKMTNIDPVDTATYYCAHHSISTIFDHWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
DrugBank_IDDB16755
Typebiotech
IndicationBebtelovimab currently has no approved indications.

Dosage Forms
Form Route Strength
Injection, solution Intravenous
87.5 mg/1mL
Target Information
Role Uniprot_ID Gene_Name Entity_Name Organism Actions Internal link
target P0DTC2 S Spike glycoprotein Severe acute respiratory syndrome coronavirus 2 antibody Link